替格瑞洛治疗急性冠状动脉综合征对患者血清炎症因子、临床疗效及安全性影响分析

The effect of ticagreloron serum inflammatory factors, clinical efficacy and safety in patients with acute coronary syndrome

目的探讨替格瑞洛治疗急性冠状动脉综合征(ACS)对患者血清炎症因子、临床疗效及安全性影响。方法选取2014年1月～2016年6月本院收治的ACS患者96例,将其按随机数字表法分为观察组35例与对照组31例,两组患者均接受常规治疗,其中对照组患者在此基础上接受阿司匹林+氯吡格雷治疗,观察组患者在此基础上接受阿司匹林+替格瑞洛治疗,连续治疗1年后,测量两组患者血清炎症因子水平,对比两组患者不良心血管事件和不良反应发生率。结果治疗前,两组患者hs-CRP、LP-PLA2等血清炎症因子水平比较差异无统计学意义(P> 0.05),治疗后两组患者hs-CRP、LP-PLA2水平较治疗前明显下降,且观察组患者hs-CRP、LP-PLA2水平明显低于对照组,差异有统计学意义(P <0.05);治疗后,观察组患者再发心绞痛、急性心肌梗死、心源性猝死等不良心血管事件发生率(6.00%)明显低于对照组(23.91%),差异有统计学意义(P <0.05);治疗后,观察组患者呼吸困难、胃肠道出血、大出血、心动过缓等不良反应发生率(8.00%)与对照组不良反应发生率(17.39%)比较,差异有统计学意义(P <0.05)。结论针对ACS患者实施替格瑞洛治疗,可明显降低其血清炎症因子水平,在减少不良心血管事件发生的同时,保证了治疗的安全性,因此临床推广应用价值较高。

Objective To explore the effect of ticagrelor on serum inflammatory factors,clinical efficacy and safety in patients with acute coronary syndrome(ACS).Methods96cases with ACS in our hospital from January2014to June2016were selected,and they were divided into the observation group(n=35)and the control group(n=31)according to random number table.The two group were both received routine treatment,the control group was received aspirin+clopidogrel on this basis,the observation group was received aspirin+ticagrelor.After1year of continuous treatment,the levels of serum inflammatory factors were measured in the two groups,and the incidence of adverse cardiovascular events and adverse reactions was compared between the two groups.Results Before treatment,there were no significant differences in serum inflammatory factors such as hs-CRP and LP-PLA2between the two groups(P>0.05).After treatment,The levels of hs-CRP and LP-PLA2in the two groups were significantly lower than those before treatment,and the levels of hs-CRP and LP-PLA2in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the incidence of adverse cardiovascular events such as angina pectoris,acute myocardial infarction,sudden cardiac death(6.00%)in the observation group was significantly lower than in the control group(23.91%)(P<0.05).The incidence of adverse reactions such as dyspnea,gastrointestinal bleeding,massive hemorrhage and bradycardia in the observation group(8.00%)was not significantly different from that in the control group(17.39%)(P>0.05).Conclusion Ticagrelor in the treatment of ACS can significantly reduce the level of serum inflammatory factors,and reduce the incidence of adverse cardiovascular events,while ensuring the safety of treatment,so the clinical application value is higher.